The IL1R1 Knockout NCI-H1703 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of IL1R1 in the NCI-H1703 human non-small cell lung carcinoma line. This loss-of-function model abrogates functional type I interleukin-1 receptor (IL-1R1) expression, enabling investigation of IL-1 signaling dependency without pharmacologic inhibition. As a heterogeneous pool of knockout cells, it captures population-level editing outcomes and reduces clonal artifacts, offering advantages for studying collective cellular responses.
NCI-H1703 is a widely used squamous cell lung carcinoma line that retains key malignant epithelial features, including robust in vitro growth and invasive potential. It serves as a relevant model for lung cancer biology, particularly for studying tumor cell-intrinsic signaling, the inflammatory microenvironment, and therapeutic responses. Its genetic and phenotypic characteristics make it well-suited for CRISPR-based gene editing to dissect pathway contributions to cancer phenotypes.
IL1R1 encodes the primary receptor for interleukin-1 (IL-1?? and IL-1??), initiating pro-inflammatory signaling. Ligand binding induces heterodimerization with IL1RAP and recruitment of MYD88, IRAK1/4, and TRAF6. This triggers activation of NF-??B and MAPK pathways, leading to AP-1-mediated transcription of IL-6, TNF-??, and other cytokines. The pathway is naturally balanced by IL-1RA. Disruption of IL1R1 in this model blocks the upstream receptor, providing a clean genetic system to study IL-1-dependent signaling cascades and downstream effector functions.
In lung carcinoma, IL-1R1 signaling promotes tumor-promoting inflammation, enhancing proliferation, survival, migration, and immune evasion. This knockout model allows dissection of tumor-intrinsic IL-1 responses from microenvironmental contributions, offering insights into how loss of IL-1R1 rewires signaling networks and alters the cytokine milieu. It is especially valuable for evaluating the role of IL-1 in driving oncogenic processes and for testing hypotheses about IL-1-targeted therapies in squamous cell lung cancer.
Applications include inflammation research, cancer immunology, drug target validation, and signal transduction studies. Representative assays with these cells involve western blotting for NF-??B and MAPK activation, RT-qPCR or ELISA for IL-6 and TNF-??, NF-??B reporter assays, and functional tests like proliferation, migration, and invasion. The polyclonal population can also serve as a platform for screening IL-1 pathway inhibitors or studying compensatory pathways. For further details or to discuss customization, please contact Ascent Research.
